Temozolomide: all 659 studies that test it

Page 5 of 7. Open to participants first (91), then studies with results posted, then the rest; newest registration first within each.

• Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed GlioblastomaTerminatedNCT02510950Phase 1
• Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade GliomasTerminatedNCT02507232Early Phase 1
• Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain TumorsCompletedNCT02502708Phase 1
• Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT MethylationTerminatedNCT02477813Phase 2
• Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior ChemotherapyStatus unknownNCT02446704Phase 1/2
• Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade GliomasStatus unknownNCT02416999Not applicable
• Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer PatientsCompletedNCT02414009Phase 2
• Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid MalignanciesCompletedNCT02392793Phase 1
• Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain MetastasesStatus unknownNCT02385136Phase 1/2
• Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed GlioblastomaCompletedNCT02364206Phase 1/2
• Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours StudyCompletedNCT02358356Phase 2
• A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma MultiformeActive, not recruitingNCT02344355Phase 2
• Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT02337426Phase 1
• A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First RelapseCompletedNCT02330991Phase 2
• Maintenance Treatment Versus Observation in Elderly Patients With PCNS LymphomaStatus unknownNCT02313389Phase 3
• Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in ChildrenCompletedNCT02308527Phase 2
• Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade GliomasCompletedNCT02263105Phase 2
• Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)CompletedNCT02248012Phase 2
• Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT02227901Phase 1
• A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade GliomasStatus unknownNCT02209428Phase 2
• A Phase II Multi-center Pilot Study of Concurrent Temozolomide and Whole Brain Irradiation in Lung Cancer and Breast Cancer Patients With Brain MetastasesStatus unknownNCT02133677Phase 2
• Preoperative Chemoradiation for GlioblastomaCompletedNCT02092038Phase 1
• Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain MetastasesWithdrawnNCT02065466Phase 1/2
• PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT02049593Phase 1
• Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed GlioblastomaTerminatedNCT02046187Phase 1/2
• ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing SarcomaCompletedNCT02044120Phase 1
• Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in GlioblastomaCompletedNCT02029573Phase 2
• Study of Sequential High-dose Chemotherapy in Children With High Risk MedulloblastomaTerminatedNCT02025881Phase 1/2
• Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma （PCNSL）Status unknownNCT01985451Phase 2
• A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70Active, not recruitingNCT01985087Phase 1/2
• Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT01957956Early Phase 1
• Temozolomide as Maintenance Therapy in Small Cell Lung CancerStatus unknownNCT01900951Phase 2
• A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade GliomaCompletedNCT01891747Phase 1
• Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing SarcomaActive, not recruitingNCT01864109Phase 2
• A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With GlioblastomaCompletedNCT01860638Phase 2
• Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From GuatemalaTerminatedNCT01857752Phase 2
• Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II TrialCompletedNCT01847235Phase 2
• A Phase III Study of Re-Irradiation in Recurrent GlioblastomaWithdrawnNCT01830101Phase 3
• Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid TumorsWithdrawnNCT01736800Phase 2
• Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS LymphomaStatus unknownNCT01735747Phase 2
• Phase-1 Study of Folinic Acid to Modulate MGMT Gene in GlioblastomaTerminatedNCT01700569Phase 1
• Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant GliomasStatus unknownNCT01670890Phase 2
• Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog PathwayTerminatedNCT01601184Phase 1/2
• Peptide Vaccine and Temozolomide for Metastatic Melanoma PatientsTerminatedNCT01543464Phase 2
• Efficacy Study of Radiotherapy Alone Versus CCRT With Temozolomide in Grade III Gliomas Without 1p/19q CodeletionStatus unknownNCT01534845Phase 2
• Metformin in Children With Relapsed or Refractory Solid TumorsCompletedNCT01528046Phase 1
• Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and AdolescentsTerminatedNCT01517776Phase 2
• Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the ElderlyCompletedNCT01502241Phase 3
• Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent GliomaCompletedNCT01480050Phase 1
• A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed GlioblastomaCompletedNCT01473901Phase 1
• Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma MultiformeCompletedNCT01435395Phase 1
• IPI Biochemotherapy for Chemonaive Patients With Metastatic MelanomaTerminatedNCT01409174Phase 1
• Olaparib and Temozolomide in Treating Patients With Relapsed GlioblastomaCompletedNCT01390571Phase 1
• Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed GlioblastomaCompletedNCT01364064Phase 3
• Vincristine and Irinotecan With or Without Temozolomide in Children and Adults With Refractory/Relapsed RhabdomyosarcomaCompletedNCT01355445Phase 2
• Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)CompletedNCT01294735Phase 1
• BG & TMZ Therapy of Glioblastoma MultiformeCompletedNCT01269424Phase 1
• Temozolomide in Elderly Patients With KPS < 70CompletedNCT01242566Phase 2
• Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT01222221Phase 1
• Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the EyeStatus unknownNCT01217398Phase 2
• Dendritic Cell Cancer Vaccine for High-grade GliomaCompletedNCT01213407Phase 2
• To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid TumorsCompletedNCT01193140Phase 2
• Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT01149850Phase 2
• Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma PatientsCompletedNCT01149109Phase 3
• Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid TumorsCompletedNCT01141244Phase 1
• Veliparib and Temozolomide in Treating Patients With Acute LeukemiaCompletedNCT01139970Phase 1
• Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb InfusionCompletedNCT01127594Phase 1
• RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaCompletedNCT01119599Phase 1
• A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian CancerCompletedNCT01113957Phase 2
• Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant GliomasStatus unknownNCT01107522Phase 1
• A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate CancerCompletedNCT01085422Phase 1
• Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord TumorsCompletedNCT01076530Phase 1
• A Phase I Study of TPI 287 - Temozolomide Combination in MelanomaTerminatedNCT01067066Phase 1
• Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous SystemCompletedNCT01048554Phase 2
• Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in AdultsCompletedNCT01043536Phase 1
• Evaluation of the Irinotecan/Bevacizumab Association for Naive Unresectable GlioblastomaCompletedNCT01022918Phase 2
• Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant MelanomaCompletedNCT01005472Phase 1
• A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS TumorsCompletedNCT00994071Phase 1
• Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade GliomaActive, not recruitingNCT00978458Phase 3
• Boron Neutron Capture Therapy, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00974987Phase 2
• Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic MelanomaCompletedNCT00970996Phase 1
• Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant MelanomaTerminatedNCT00961844Phase 1/2
• Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With GlioblastomaCompletedNCT00960492Phase 1
• ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS TumorsCompletedNCT00946335Phase 1
• Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent GlioblastomaCompletedNCT00941460Phase 2
• Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma MultiformeTerminatedNCT00915694Phase 1
• Treatment Strategy for Low-grade GliomasTerminatedNCT00897377Phase 3
• Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed GlioblastomaTerminatedNCT00895960Phase 1
• Methoxyamine and Temozolomide in Treating Patients With Advanced Solid TumorsCompletedNCT00892385Phase 1
• Proton Chemoradiotherapy for High-Risk Soft Tissue SarcomasWithdrawnNCT00881595Phase 2
• Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast CancerStatus unknownNCT00875355Phase 2
• Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)CompletedNCT00831545Phase 2
• Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma MultiformeCompletedNCT00820963Phase 3
• Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)CompletedNCT00817284Phase 2
• A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid TumorsTerminatedNCT00811993Phase 1
• Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV MelanomaStatus unknownNCT00811759Phase 1/2
• A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed GlioblastomaCompletedNCT00792012Phase 1
• A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid TumorsCompletedNCT00786669Phase 1
• SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)CompletedNCT00783393Phase 2
• ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00770471Phase 1

← Temozolomide overview